Literature DB >> 15915449

Quantitative analysis of 23-hydroxybetulinic acid in mouse plasma using electrospray liquid chromatography/mass spectrometry.

Min Yang1, Guang Ji Wang, Su Jun Wang, Xiao Tian Li, Yu Ping Xu, Song Pei Wang, Jing De Xiang, Shang Ren Pan, Guo Xian Cao, Wen Cai Ye.   

Abstract

23-Hydroxybetulinic acid is a newly isolated derivative of betulinic acid. The agent exhibits potential anti-tumor activity and functions in this regard via apoptosis. In support of pharmacokinetic and toxicological evaluations, a new assay based on liquid chromatography/mass spectrometry (LC/MS) was developed for the quantitative analysis of 23-hydroxybetulinic acid. Sample preparation consisted of extraction of the plasma by the addition of methylene chloride followed by centrifugation. Aliquots of the supernatant were analyzed using an isocratic reversed-phase high-performance liquid chromatography (HPLC) system coupled to a negative ion electrospray mass spectrometer. Molecules of 23-hydroxybetulinic acid and the internal standard limonin were detected using selected ion monitoring at m/z 471 and 469, respectively. The limit of detection of 23-hydroxybetulinic acid was 0.05 pg (0.11 fmol) injected on-column (10 pg/mL, 5 microL injection volume), and the limit of quantitation was 10 pg (21.19 fmol, 2 ng/mL, 5 muL injection volume). 23-Hydroxybetulinic acid was stable in plasma samples at -20 degrees C for at least 3 weeks. The intra-day and inter-day coefficients of variation of the assay were 3.0 and 4.8%, respectively. The utility of the assay was demonstrated by measuring 23-hydroxybetulinicacid in mouse plasma following intragastric administration (IG) in vivo. Pharmacokinetic parameters were calculated using the 3P97 pharmacokinetic software package. A two-compartment, first-order model was selected for pharmacokinetic modeling. The result showed that after IG of 200 mg/kg 23-hydroxybetulinic acid, the plasma concentrations reached peaks at 2 h with C(max) of 3.1 microg/mL. The 200 mg/kg 23-hydroxybetulinic acid suspension IG doses were found to have long elimination half-lives of 25.6 h and low bioavailability of 2.3%. No interference was noted due to endogenous substances. These analytical methods should be of value in future studies related to the development and characterization of 23-hydroxybetulinic acid. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15915449     DOI: 10.1002/rcm.1961

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  4 in total

Review 1.  Pentacyclic Triterpene Bioavailability: An Overview of In Vitro and In Vivo Studies.

Authors:  Niege A J C Furtado; Laetitia Pirson; Hélène Edelberg; Lisa M Miranda; Cristina Loira-Pastoriza; Véronique Preat; Yvan Larondelle; Christelle M André
Journal:  Molecules       Date:  2017-03-04       Impact factor: 4.411

Review 2.  Onco-Preventive and Chemo-Protective Effects of Apple Bioactive Compounds.

Authors:  Linda Nezbedova; Tony McGhie; Mark Christensen; Julian Heyes; Noha Ahmed Nasef; Sunali Mehta
Journal:  Nutrients       Date:  2021-11-11       Impact factor: 5.717

3.  bba, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10).

Authors:  Jun-Jiang Chen; Atish Patel; Kamlesh Sodani; Zhi-Jie Xiao; Amit K Tiwari; Dong-Mei Zhang; Ying-Jie Li; Dong-Hua Yang; Wen-Cai Ye; Si-Dong Chen; Zhe-Sheng Chen
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

Review 4.  Mechanistic Perspectives of Maslinic Acid in Targeting Inflammation.

Authors:  Wei Hsum Yap; Yang Mooi Lim
Journal:  Biochem Res Int       Date:  2015-09-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.